Hyderabad: Pfizer filed the possible patent infringement case against Aurobindo Pharma in the US District Court for the District of Delaware and Dr Reddy's in the New Jersey court.

Pfizer in its petition stated that the Indian drug makers had submitted abbreviated new drug application(ANDA) to the US FDA seeking approval to engage in the commercial manufacture, sale and importation of the intended generic drugs of ibrance capsules, 75 mg, 100 mg, and 125 mg prior to the expiration of the 730 patent.

The patent violation petition was filed on Jan 11 at the US District Court for the District Court of Delaware, according to a court document reviewed by Cogencis. In November, Aurobindo Pharma had informed Pfizer about filing an Abbreviated New Drug Application with the US FDA, seeking approval to make a generic of Xeljanz, Tofacitinib, in 5- and 10-mg dosages.

Xeljanz is used to treat rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. Pfizer sought the order to prevent Aurobindo from making and selling the drug in the US before its patent expiry.

EU secures deal to double Pfizer-BioNTech vaccine supply

Government jobs in West Bengal offer attractive salaries

Govt approval expects to vehicle scrappage policy soon: Nitin Gadkari